| Journal | Journal of child and adolescent psychopharmacology |
| Study Type | Cohort |
| Population | Human participants |
This large real-world study from Israel’s national health system provides the first comprehensive data on medical cannabis prescribing patterns for autism spectrum disorder. It reveals significant gaps between clinical guidelines and actual practice, with implications for patient safety and regulatory oversight.
This retrospective cohort study analyzed electronic medical records from Clalit Health Services to examine medical cannabis prescribing for autism patients. Only 1.2% of individuals with autism received medical cannabis prescriptions, yet 4.3% of these prescriptions went to children under 5 years old. Israeli guidelines require prior trials of two FDA-approved antipsychotics before cannabis authorization for autism with severe behavioral disturbances. The cannabis-prescribed group received their autism diagnosis earlier (median age 3 years), suggesting these may represent more severe cases requiring earlier intervention.
“I find it concerning that very young children are receiving medical cannabis for autism when we lack safety and efficacy data in this vulnerable population. The low overall prescribing rate suggests appropriate caution, but the early prescribing age raises questions about guideline adherence and clinical decision-making.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- How common is medical cannabis prescribing for autism in clinical practice?
- What are the age restrictions for medical cannabis use in autism?
- What clinical characteristics are associated with medical cannabis prescribing in autism?
- Are clinicians following established guidelines when prescribing medical cannabis for autism?
- What should clinicians know about the evidence base for medical cannabis in autism?
FAQ
How common is medical cannabis prescribing for autism in clinical practice?
According to this large Israeli health system study, only 1.2% of individuals with autism were prescribed medical cannabis. This suggests that despite growing clinical interest, medical cannabis remains a rarely used treatment option for autism spectrum disorders in real-world clinical settings.
What are the age restrictions for medical cannabis use in autism?
The study found that 4.3% of medical cannabis prescriptions were issued to children under 5 years of age. However, Israel’s national guidelines require strict Ministry of Health approval and prior trials of two FDA-approved antipsychotics before medical cannabis can be prescribed for autism with severe behavioral disturbances.
What clinical characteristics are associated with medical cannabis prescribing in autism?
Individuals prescribed medical cannabis were diagnosed with autism earlier, with a median age of 3 years at diagnosis. This suggests that earlier diagnosis and potentially more severe presentations may be factors in clinical decision-making for medical cannabis consideration.
Are clinicians following established guidelines when prescribing medical cannabis for autism?
The study aimed to evaluate adherence to Israel’s national guidelines, which require prior trials of two FDA-approved antipsychotics before medical cannabis prescription. However, the provided study excerpt does not include the adherence results, indicating this remains an important area for clinical oversight and quality improvement.
What should clinicians know about the evidence base for medical cannabis in autism?
The study notes that evidence for medical cannabis effectiveness in autism “has begun to accumulate but remains limited.” This indicates that while some preliminary data exists, clinicians should approach medical cannabis as an experimental treatment option that requires careful consideration of risks and benefits, particularly in pediatric populations.